CSP-2503

In today's world, CSP-2503 has acquired unprecedented relevance. Whether due to its impact on society, its influence on culture or its significance in the economic sphere, CSP-2503 has managed to capture the attention and interest of experts and fans alike. In this article, we will comprehensively analyze all the facets linked to CSP-2503, exploring its origin, evolution and consequences. Furthermore, we will examine in detail its role in the current context, as well as the possible future projections that could arise from its presence on the global scene. Likewise, we will address the various perspectives and opinions around CSP-2503, with the aim of providing our readers with a complete and nuanced overview of this topic that is so relevant today.

Chemical compound

Pharmaceutical compound

CSP-2503

Clinical data
ATC code	none
Identifiers
IUPAC name 2-hexahydropyrrolopyrazine-1,4-dione
CAS Number	581813-10-7
PubChem CID	10317515
ChemSpider	8492979 Y
UNII	87UKL3XE5X
ChEMBL	ChEMBL285066 Y
Chemical and physical data
Formula	C22H26N4O2
Molar mass	378.476 g·mol−1
3D model (JSmol)	Interactive image
SMILES O=C4N5CCCC5C(=O)N(CN3CCN(c2c1ccccc1ccc2)CC3)C4
InChI InChI=1S/C22H26N4O2/c27-21-15-25(22(28)20-9-4-10-26(20)21)16-23-11-13-24(14-12-23)19-8-3-6-17-5-1-2-7-18(17)19/h1-3,5-8,20H,4,9-16H2 Y Key:CTZWGZSINBFHFD-UHFFFAOYSA-N Y
(verify)

CSP-2503 is a potent and selective 5-HT_1A receptor agonist, 5-HT_2A receptor antagonist, and 5-HT₃ receptor antagonist of the naphthylpiperazine class.^[1] First synthesized in 2003, it was designed based on computational models and QSAR studies.^[2][3] In rat studies, CSP-2503 has demonstrated anxiolytic effects, and thus has been suggested as a treatment for anxiety in humans with a multimodal mechanism of action.^[1]

See also

• Naphthylpiperazine
• S-14,671
• S-14,506

References

1. ^ ^{a b} Delgado M, Caicoya AG, Greciano V, et al. (March 2005). "Anxiolytic-like effect of a serotonergic ligand with high affinity for 5-HT1A, 5-HT2A and 5-HT3 receptors". European Journal of Pharmacology. 511 (1): 9–19. doi:10.1016/j.ejphar.2005.01.032. PMID 15777774.
2. ^ López-Rodríguez ML, Morcillo MJ, Fernández E, et al. (April 2003). "Design and synthesis of S-(−)-2-methyl]-1,4-dioxoperhydropyrrolopyrazine (CSP-2503) using computational simulation. A 5-HT1A receptor agonist". Bioorganic & Medicinal Chemistry Letters. 13 (8): 1429–32. doi:10.1016/S0960-894X(03)00160-4. PMID 12668005.
3. ^ López-Rodríguez ML, Morcillo MJ, Fernández E, et al. (April 2005). "Synthesis and structure-activity relationships of a new model of arylpiperazines. 8. Computational simulation of ligand-receptor interaction of 5-HT(1A)R agonists with selectivity over alpha1-adrenoceptors". Journal of Medicinal Chemistry. 48 (7): 2548–58. doi:10.1021/jm048999e. PMID 15801844.